F-652 is under clinical development by Evive Biotech and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect F-652’s likelihood of approval (LoA) and phase transition for Graft Versus Host Disease (GVHD) took place on 19 Jul 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their F-652 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
F-652 is under development for the treatment of moderate to severe covid-19 , covid-19 pneumonia, acute pancreatitis, chronic acute liver failure, alcoholic hepatitis and graft versus host disease (GVHD). It is administered intravenously. It is a recombinant fusion protein containing a recombinant human interleukin 22-human immunoglobulin Fc fusion protein. The drug candidate targets interleukin-22 receptors. The drug candidate is developed based on DiKine technology. It was also under development for the treatment of inflammation and fatty liver disease and moderate to severe coronavirus disease 2019 (COVID-19).
Evive Biotech overview
Evive Biotech formerly Generon (Shanghai) is a biotechnology company that offers research and development of therapeutic biologics. The company discovers, develops and produces biomedicines. Its pipeline products include F-627, F-652, F-899 and ITabs. Evive Biotech’s F-627 is a recombinant fusion protein with human granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia. The company’s F-637 is under development, which is intended to treat inflammatory diseases with tissue injuries and immunologic disorders; and F-899, under development, which is intended to treat patients with growth deficiency and wasting diseases. Its ITabs platform all together binds to CD3 molecules on human T cells and to specific tumor antigens. Evive Biotech is headquartered in Shanghai, China.
Quick View F-652 LOA Data
|Highest Development Stage|